J. Milone

发表

Allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndrome: Experience of the Argentinean Group of Bone Marrow Transplantation (GATMO)

G. Remaggi, J. Garcia, J. Arbelbide, 2016, Hematology.

Dasatinib Dose-Optimization in Chronic Phase Chronic Myeloid Leukemia (CML-CP): Two-Year Data from CA180-034 Show Equivalent Long-Term Efficacy and Improved Safety with 100 Mg Once Daily Dose

Martin C. Müller, H. Kantarjian, P. Rousselot, 2008 .

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

M. Baccarani, E. Vellenga, H. Kantarjian, 2012, Blood.

Bosutinib (BOS) as third-line therapy for chronic phase (CP) chronic myeloid leukemia (CML) following failure with imatinib (IM) and dasatinib (DAS) or nilotinib (NIL).

M. Baccarani, H. Kantarjian, J. Cortes, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Autologous stem cell transplantation for patients with chronic myeloid leukemia

B. Koziner, G. Milone, C. Canepa, 2002, Cancer.

Clinical characteristics and evolution of hematological patients and COVID-19 in Argentina: a report from the Argentine Society of Hematology.

G. Remaggi, S. Zabaljauregui, M. Ventriglia, 2021, Medicina.

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.

Andreas Hochhaus, R. Collins, H. Kantarjian, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dasatinib 50 mg or 70 mg BID compared to 100 mg or 140 mg QD in patients with CML in chronic phase (CP) who are resistant or intolerant to imatinib: One-year results of CA180034

H. Kantarjian, P. Rousselot, A. Hochhaus, 2007 .

Chapter 13 Acute Lymphoblastic Leukemia ( ALL ) Philadelphia Positive ( Ph 1 ) ( Incidence Classifications , Prognostic Factor in ALL Principles of ALL Therapy )

J. Milone, A. Enrico, 2019 .

Acute Lymphoblastic Leukemia (ALL) Philadelphia Positive (Ph1) (Incidence Classifications, Prognostic Factor in ALL Principles of ALL Therapy)

J. Milone, A. Enrico, 2013 .

Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia

J. Milone, A. Enrico, 2009, Leukemia & lymphoma.

Multivariate analyses of prognostic factors associated with hematopoietic recovery in autograft patients with different sources of progenitor cells. A GATMO experience. Argintine Group of Bone Marrow Transplant.

C. Corrado, L. Feldman, B. Koziner, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[Bone marrow transplantation in chronic myeloid leukemia].

J. Napal, J. Milone, M. Prates, 1999, Medicina.

Real-world outcomes for the treatment of relapsed/refractory multiple myeloma patients with lenalidomide-dexamethasone combinations in a Latin American country. A retrospective cohort study from grupo argentino de mieloma múltiple

D. Fantl, P. Ochoa, P. Duarte, 2021, Expert review of hematology.

Complete response in severe thrombotic microangiopathy post bone marrow transplantation (BMT-TM) after multiple plasmaphereses

J. Napal, J. Milone, J. Bordone, 1998, Bone Marrow Transplantation.

Acute Lymphoblastic Leukemia ( Ph + ALL )

J. Milone, E. Alicia, 2018 .

Bone Marrow Transplantation (BMT) in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

J. Milone, E. Alicia, 2013 .

Dasatinib (SPRYCEL®) 50mg or 70mg BID Versus 100mg or 140mg QD in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Resistant or Intolerant to Imatinib: Results of the CA180-034 Study.

H. Kantarjian, P. Rousselot, A. Hochhaus, 2006 .

Graft versus host disease in autologous stem cell transplantation.

H. Buschiazzo, J. Napal, J. Milone, 1999, Journal of experimental & clinical cancer research : CR.

[Umbilical cord hematopoietic progenitor cells bank].

J. Milone, J. Bordone, A. Uranga, 2001, Medicina.

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Francisco Cervantes, Ryuzo Ohno, Richard E. Clark, 2013, Blood.

Clinical outcome of chronic myeloid leukemia imatinib-resistant patients: do BCR–ABL kinase domain mutations affect patient survival? First multicenter Argentinean study

M. Bianchini, R. Bengió, I. Larripa, 2011, Leukemia & lymphoma.

Comparison of matched sibling, unrelated and haploidentical donors in hematopoietic stem cell transplantation. A real-world experience from the Argentine Group for Bone Marrow Transplantation and Cell Therapy (GATMO-TC).

S. Yantorno, J. Garcia, A. Basquiera, 2020, Medicina.

Response to single-agent thalidomide and eligibility to undergo autotransplant for patients with multiple myeloma refractory to VAD

J. Napal, J. Milone, V. Prates, 2003, Bone Marrow Transplantation.

Cell processing practices in Argentina: report of a multicenter survey.

L. Feldman, B. Koziner, A. Kohan, 2001, Cytotherapy.

Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: does achievement of a stable major molecular response at any time point identify a privileged group of patients? A multicenter experience in Argentina and Uruguay.

Juan F. García, R. Bengió, M. Pavlovsky, 2011, Clinical lymphoma, myeloma & leukemia.

T-Cell Lymphomas in South America and Europe

J. Vose, S. Montoto, J. Connors, 2012, Revista brasileira de hematologia e hemoterapia.

Vindesine, prednisone, and daunomycin in acute lymphoblastic leukemia in relapse

J. Milone, S. Pavlovsky, E. Dibar, 2004, Cancer Chemotherapy and Pharmacology.

Allogeneic hematopoietic stem cell transplantation in the elderly. Predicting the risk for non relapse mortality.

G. Remaggi, J. Garcia, A. Basquiera, 2015, Medicina.

The First Report of Familial Adult T-cell Leukemia/Lymphoma in Argentina

J. Milone, M. Cobos, V. Prates, 2000, Leukemia & lymphoma.

[Adult HTLV-I positive leukemia-lymphoma in Argentina].

C. Dufour, D. Fantl, J. Milone, 1995, Sangre.

Dasatinib in imatinib‐resistant or ‐intolerant chronic‐phase, chronic myeloid leukemia patients: 7‐year follow‐up of study CA180‐034

H. Kantarjian, J. Cortes, G. Saglio, 2016, American journal of hematology.

Dasatinib dose-optimization study in chronic phase chronic myeloid leukemia (CML-CP): Three-year follow-up with dasatinib 100 mg once daily and landmark analysis of cytogenetic response and progression-free survival (PFS).

H. Kantarjian, R. Stone, P. Rousselot, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PH negative acute lymphoblastic leukemia in adolescents and young adults treated according a MRD adapted BFM ALL IC 2009 protocol: Argentine real-world data on 171 patients

M. M. Mela Osorio, L. Ferrari, M. Moirano, 2023, Annals of Hematology.

Rapid Infusion of Rituximab (RIR) Is Well Tolerated and Can Safely Be Delivered in Patients with Lymphoproliferative Diseases.

J. Milone, V. Prates, G. Juan, 2007 .

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

J. Radich, H. Kantarjian, D. B. Yehuda, 2013, Blood.